Concepts (137)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Simian Acquired Immunodeficiency Syndrome | 5 | 2017 | 17 | 1.610 |
Why?
|
| HIV-1 | 7 | 2023 | 235 | 1.310 |
Why?
|
| Pan troglodytes | 4 | 2017 | 8 | 1.290 |
Why?
|
| Simian Immunodeficiency Virus | 4 | 2017 | 16 | 1.220 |
Why?
|
| Ape Diseases | 2 | 2017 | 2 | 1.050 |
Why?
|
| HIV Infections | 6 | 2023 | 477 | 1.020 |
Why?
|
| Candidiasis | 1 | 2025 | 28 | 0.950 |
Why?
|
| Air Microbiology | 1 | 2025 | 5 | 0.950 |
Why?
|
| Environmental Monitoring | 1 | 2025 | 11 | 0.950 |
Why?
|
| Respiratory Tract Infections | 1 | 2025 | 25 | 0.940 |
Why?
|
| beta Catenin | 2 | 2022 | 63 | 0.890 |
Why?
|
| Laboratories, Hospital | 1 | 2024 | 5 | 0.860 |
Why?
|
| Cross Infection | 1 | 2025 | 309 | 0.780 |
Why?
|
| Antibodies, Neutralizing | 2 | 2018 | 23 | 0.620 |
Why?
|
| Anti-Retroviral Agents | 2 | 2020 | 17 | 0.590 |
Why?
|
| Bacteria | 1 | 2015 | 73 | 0.480 |
Why?
|
| Cross Reactions | 1 | 2015 | 9 | 0.480 |
Why?
|
| HIV Antibodies | 1 | 2015 | 15 | 0.470 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2015 | 162 | 0.420 |
Why?
|
| Animals | 9 | 2023 | 3682 | 0.340 |
Why?
|
| Humans | 15 | 2025 | 27309 | 0.330 |
Why?
|
| Astrocytes | 2 | 2021 | 147 | 0.310 |
Why?
|
| Genome, Viral | 2 | 2025 | 14 | 0.290 |
Why?
|
| Chicago | 3 | 2025 | 953 | 0.270 |
Why?
|
| CD4-Positive T-Lymphocytes | 4 | 2022 | 107 | 0.270 |
Why?
|
| Disease Outbreaks | 2 | 2024 | 81 | 0.260 |
Why?
|
| Phylogeny | 2 | 2025 | 54 | 0.260 |
Why?
|
| Genome, Fungal | 1 | 2025 | 4 | 0.240 |
Why?
|
| Whole Genome Sequencing | 1 | 2025 | 9 | 0.240 |
Why?
|
| Genomics | 1 | 2025 | 68 | 0.240 |
Why?
|
| Anti-HIV Agents | 2 | 2023 | 68 | 0.240 |
Why?
|
| Vaccination | 1 | 2024 | 35 | 0.220 |
Why?
|
| Hospitals | 1 | 2025 | 170 | 0.220 |
Why?
|
| Public Health Surveillance | 1 | 2024 | 11 | 0.220 |
Why?
|
| Virus Replication | 2 | 2021 | 51 | 0.210 |
Why?
|
| Public Health | 1 | 2024 | 71 | 0.210 |
Why?
|
| Kidney Diseases | 1 | 2024 | 72 | 0.210 |
Why?
|
| Male | 7 | 2025 | 14887 | 0.200 |
Why?
|
| Diabetes Mellitus | 1 | 2024 | 130 | 0.200 |
Why?
|
| Virus Activation | 1 | 2022 | 12 | 0.190 |
Why?
|
| Virus Latency | 1 | 2022 | 16 | 0.190 |
Why?
|
| Zika Virus Infection | 1 | 2021 | 3 | 0.180 |
Why?
|
| Zika Virus | 1 | 2021 | 3 | 0.180 |
Why?
|
| Fetus | 1 | 2021 | 37 | 0.180 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2020 | 53 | 0.180 |
Why?
|
| Viral Load | 2 | 2020 | 75 | 0.180 |
Why?
|
| Receptors, IgG | 1 | 2020 | 12 | 0.170 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2020 | 41 | 0.170 |
Why?
|
| Virus Release | 1 | 2020 | 5 | 0.170 |
Why?
|
| Blood-Brain Barrier | 1 | 2020 | 38 | 0.170 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2020 | 116 | 0.160 |
Why?
|
| Tanzania | 2 | 2016 | 2 | 0.160 |
Why?
|
| Neutralization Tests | 2 | 2018 | 8 | 0.160 |
Why?
|
| Female | 6 | 2025 | 15334 | 0.160 |
Why?
|
| env Gene Products, Human Immunodeficiency Virus | 1 | 2018 | 3 | 0.150 |
Why?
|
| Polysaccharides | 1 | 2018 | 12 | 0.150 |
Why?
|
| Hippocampus | 1 | 2020 | 275 | 0.140 |
Why?
|
| Drug Resistance, Viral | 1 | 2017 | 14 | 0.140 |
Why?
|
| Virion | 2 | 2017 | 15 | 0.140 |
Why?
|
| RNA, Viral | 1 | 2017 | 48 | 0.140 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2017 | 61 | 0.130 |
Why?
|
| Interferon Type I | 1 | 2017 | 14 | 0.130 |
Why?
|
| Social Dominance | 1 | 2016 | 1 | 0.130 |
Why?
|
| Viral Envelope Proteins | 2 | 2013 | 15 | 0.130 |
Why?
|
| Adenoviruses, Simian | 1 | 2015 | 1 | 0.120 |
Why?
|
| DNA Viruses | 1 | 2015 | 6 | 0.120 |
Why?
|
| Metagenome | 1 | 2015 | 17 | 0.120 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2015 | 57 | 0.120 |
Why?
|
| Mutation | 1 | 2017 | 353 | 0.120 |
Why?
|
| Feces | 1 | 2015 | 103 | 0.120 |
Why?
|
| Gorilla gorilla | 1 | 2015 | 1 | 0.120 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2015 | 6 | 0.120 |
Why?
|
| Middle Aged | 2 | 2025 | 9068 | 0.120 |
Why?
|
| Health Status | 1 | 2016 | 219 | 0.110 |
Why?
|
| Caloric Restriction | 1 | 2013 | 16 | 0.100 |
Why?
|
| Dendritic Cells | 1 | 2013 | 36 | 0.100 |
Why?
|
| Age of Onset | 1 | 2013 | 95 | 0.100 |
Why?
|
| Energy Metabolism | 1 | 2013 | 53 | 0.100 |
Why?
|
| Sarcopenia | 1 | 2013 | 31 | 0.100 |
Why?
|
| Brain | 1 | 2021 | 1648 | 0.100 |
Why?
|
| Mucous Membrane | 1 | 2012 | 30 | 0.090 |
Why?
|
| Phenotype | 1 | 2013 | 313 | 0.090 |
Why?
|
| Mice | 2 | 2023 | 1450 | 0.070 |
Why?
|
| Viral Vaccines | 1 | 2024 | 3 | 0.060 |
Why?
|
| Antibodies, Viral | 1 | 2024 | 58 | 0.060 |
Why?
|
| Lamivudine | 1 | 2023 | 9 | 0.050 |
Why?
|
| Electronic Health Records | 1 | 2024 | 74 | 0.050 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2023 | 55 | 0.050 |
Why?
|
| Vero Cells | 1 | 2021 | 8 | 0.050 |
Why?
|
| Virus Internalization | 1 | 2021 | 19 | 0.050 |
Why?
|
| Illinois | 1 | 2022 | 250 | 0.050 |
Why?
|
| Aged | 2 | 2024 | 9119 | 0.040 |
Why?
|
| Cell Separation | 1 | 2020 | 25 | 0.040 |
Why?
|
| Flow Cytometry | 1 | 2020 | 112 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2020 | 30 | 0.040 |
Why?
|
| Kidney | 1 | 2021 | 152 | 0.040 |
Why?
|
| Mice, SCID | 1 | 2020 | 45 | 0.040 |
Why?
|
| Cell Line, Tumor | 1 | 2020 | 271 | 0.040 |
Why?
|
| Mice, Knockout | 1 | 2020 | 311 | 0.040 |
Why?
|
| Conserved Sequence | 1 | 2018 | 9 | 0.040 |
Why?
|
| Computational Biology | 1 | 2018 | 21 | 0.040 |
Why?
|
| HEK293 Cells | 1 | 2018 | 67 | 0.040 |
Why?
|
| Adolescent | 1 | 2024 | 2185 | 0.040 |
Why?
|
| Kinetics | 1 | 2018 | 180 | 0.040 |
Why?
|
| Models, Molecular | 1 | 2018 | 83 | 0.040 |
Why?
|
| Young Adult | 1 | 2024 | 2032 | 0.040 |
Why?
|
| Vaginal Douching | 1 | 2017 | 4 | 0.030 |
Why?
|
| Semen | 1 | 2017 | 3 | 0.030 |
Why?
|
| Host-Pathogen Interactions | 1 | 2017 | 17 | 0.030 |
Why?
|
| Respiratory Tract Diseases | 1 | 2016 | 7 | 0.030 |
Why?
|
| Diarrhea | 1 | 2016 | 37 | 0.030 |
Why?
|
| Skin Diseases | 1 | 2016 | 25 | 0.030 |
Why?
|
| Weight Loss | 1 | 2016 | 127 | 0.030 |
Why?
|
| Sex Factors | 1 | 2016 | 469 | 0.030 |
Why?
|
| Prevalence | 1 | 2016 | 458 | 0.030 |
Why?
|
| Age Factors | 1 | 2016 | 779 | 0.030 |
Why?
|
| Electron Transport Complex IV | 1 | 2013 | 2 | 0.030 |
Why?
|
| Oxidative Phosphorylation | 1 | 2013 | 6 | 0.030 |
Why?
|
| Cloning, Molecular | 1 | 2013 | 29 | 0.030 |
Why?
|
| Oxidation-Reduction | 1 | 2013 | 66 | 0.030 |
Why?
|
| Lipid Metabolism | 1 | 2013 | 38 | 0.030 |
Why?
|
| Macaca mulatta | 1 | 2013 | 61 | 0.030 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2013 | 42 | 0.030 |
Why?
|
| Mitochondria | 1 | 2013 | 66 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2013 | 57 | 0.030 |
Why?
|
| Base Sequence | 1 | 2013 | 108 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2013 | 92 | 0.030 |
Why?
|
| Molecular Sequence Data | 1 | 2013 | 194 | 0.030 |
Why?
|
| Linear Models | 1 | 2013 | 247 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2013 | 169 | 0.020 |
Why?
|
| Macaca nemestrina | 1 | 2012 | 3 | 0.020 |
Why?
|
| Receptors, CCR5 | 1 | 2012 | 14 | 0.020 |
Why?
|
| Evolution, Molecular | 1 | 2012 | 7 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2016 | 1380 | 0.020 |
Why?
|
| Adult | 1 | 2024 | 7946 | 0.020 |
Why?
|
| Disease Susceptibility | 1 | 2012 | 70 | 0.020 |
Why?
|
| Aging | 1 | 2013 | 1555 | 0.010 |
Why?
|